Alexion Pharmaceuticals's annual revenues are over $500 million (see exact revenue data) and has over 1,000 employees. It is classified as operating in the Scientific Research & Development Services industry.
Note: Alexion Pharmaceuticals's revenues are gauged from an analysis of company filings.
Trademark applications show the products and services that Alexion Pharmaceuticals is developing and marketing.
Alexion Pharmaceuticals's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets.
Trademarks may include brand names, product names, logos and slogans.
Patent applications show Alexion Pharmaceuticals's intellectual property,
its current capabilities and future direction.
Alexion Pharmaceuticals has applied for 92 patents since 2009.
Alexion Pharmaceuticals's most recent patent was filed in September 2018 for Methods Of Producing Anti-c5a Antibodies.The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
Complete list of patent applications
Determine whether Alexion Pharmaceuticals grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof Alexion Pharmaceuticals is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
Market Share of Competition: Alexion Pharmaceuticals vs. Largest Competitors
A competitive analysis shows these companies are in the same general field as Alexion Pharmaceuticals, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Alexion Pharmaceuticals.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Alexion Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.